LAB fluidigm.com Total Debt to Capital

LAB (Fluidigm) - company brandmark

The debt-to-equity ratio reflects the financial standing of Standard BioTools Inc. (LAB), where the value remains around 0.05. This results from cost optimization and synergies following the asset merger. Standard BioTools Inc. (LAB) is creating a unique cellular analysis environment through cytometry, while simultaneously implementing eco-production standards and reducing harmful emissions within its diagnostic complexes.

LAB: Standard BioTools Total Debt to Capital 04/28/2023 - 10/27/2026

Comprehensive metric breakdowns and analytics for Standard BioTools Corp (LAB)

- price and consensus price forecast:
Stock Price Standard BioTools|LAB - Average Forecast Price
- market capitalization data:
Market Capitalization Standard BioTools|LAB - Business Value
- book capitalization data:
Book Value per Share Standard BioTools|LAB - Book Capitalization|Market Value to Book Value Ratio fluidigm.com|LAB - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Standard BioTools Inc.|LAB - Long-Term Debt to Capital|Short-Term Debt to Equity Standard BioTools Inc.|LAB - Company Debts|Debt to Book Value Standard BioTools
Comprehensive company analysis:Standard BioTools LAB
Finished products of Standard BioTools Inc.

Scaling the delivery of proteomic analysis systems for Standard BioTools Inc. (LAB) requires precise management of borrowed capital. This metric is calculated as the ratio of total liabilities to equity, determining the degree of financial leverage. It serves as a stress test for the model's resilience against external shocks and liquidity risk. The stability of the organization's total debt-to-equity ratio confirms a balance between expansion and solvency. This chart's dynamics allow for an assessment of the efficiency of the debt load.

Key competitors

Total Debt to Capital A (Agilent)|Debt to Capital Quest Diagnostics Inc.|Total Debt to Capital Illumina Corp ILMN|Debt to Equity Ratio Exact Sciences Inc. (EXAS)|Total Debt to Capital RVTY (Revvity, Inc.)|bio-rad.com - Total Debt to Capital|Anbio (NNNN) - Debt to Equity|SHC - Debt to Equity Ratio|QDEL: Total Debt to Capital|OPK (OPKO Health Corp.) - Total Debt to Capital|Debt to Equity CareDx Inc|Debt to Equity maravai.com (MRVI)|Fulgent Genetics - Total Debt to Equity Ratio|Debt to Capital CTKB (Cytek Biosciences Inc)|Debt to Equity OSUR|Total Debt to Capital Coefficient Exagen Inc XGN|Total Debt to Capital MDXH (MDxHealth SA)|LUCD: Total Debt to Capital Coefficient|prenetics.com - Debt to Equity|IMDX (Insight Molecular Diagnostics Inc) - Total Debt to Capital Coefficient|TRIB: Debt to Equity|Total Debt to Capital Coefficient ProPhase Labs Corp (PRPH)|Total Debt to Equity Ratio Ainos, Inc.|Aggregate Debt to Capital codiagnostics.com (CODX)|Total Debt to Capital HSCS (HeartSciences)|Biomerica Inc. - Total Debt to Capital|Cardio Diagnostics Holdings, Inc. (CDIO) - Debt to Equity|VRAX - Debt to Equity Ratio|Total Debt to Capital Bluejay Diagnostics|aspirawh.com (AWH) - Debt to Equity Ratio|AXDX (Accelerate Diagnostics, Inc.) - Total Debt to Capital|Total Debt to Capital CNTG|Enzo Biochem, Inc. (ENZ) - Debt to Equity|All Debt to Shareholders' Equity Ratio fresh2.co (FRES)|GENE - Total Debt to Capital|ME - Debt to Equity Ratio|Total Debt to Equity Ratio Psychemedics Corporation (PMD)